SI1154993T1 - Thioamide derivatives - Google Patents

Thioamide derivatives

Info

Publication number
SI1154993T1
SI1154993T1 SI200030513T SI200030513T SI1154993T1 SI 1154993 T1 SI1154993 T1 SI 1154993T1 SI 200030513 T SI200030513 T SI 200030513T SI 200030513 T SI200030513 T SI 200030513T SI 1154993 T1 SI1154993 T1 SI 1154993T1
Authority
SI
Slovenia
Prior art keywords
thioamide derivatives
vcam
vla
asthma
discovered
Prior art date
Application number
SI200030513T
Other languages
English (en)
Slovenian (sl)
Inventor
Kenneth Gregory Hull
Achytharao Sidduri
Jefferson Wright Tilley
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of SI1154993T1 publication Critical patent/SI1154993T1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00Thiocarboxylic acids
    • C07C327/38Amides of thiocarboxylic acids
    • C07C327/46Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00Thiocarboxylic acids
    • C07C327/38Amides of thiocarboxylic acids
    • C07C327/48Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to carbon atoms of six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56Amides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30Oxygen or sulfur atoms
    • C07D233/32One oxygen atom
    • C07D233/38One oxygen atom with acyl radicals or hetero atoms directly attached to ring nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/04Systems containing only non-condensed rings with a four-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Gyroscopes (AREA)
  • Liquid Crystal Substances (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
SI200030513T 1999-02-18 2000-02-10 Thioamide derivatives SI1154993T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12047599P 1999-02-18 1999-02-18
PCT/EP2000/001058 WO2000048994A1 (en) 1999-02-18 2000-02-10 Thioamide derivatives
EP00903680A EP1154993B1 (en) 1999-02-18 2000-02-10 Thioamide derivatives

Publications (1)

Publication Number Publication Date
SI1154993T1 true SI1154993T1 (en) 2004-12-31

Family

ID=22390545

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200030513T SI1154993T1 (en) 1999-02-18 2000-02-10 Thioamide derivatives

Country Status (29)

Country Link
US (6) US6288267B1 (id)
EP (1) EP1154993B1 (id)
JP (1) JP2002537286A (id)
KR (1) KR100649819B1 (id)
CN (1) CN1213025C (id)
AT (1) ATE278664T1 (id)
AU (1) AU773388B2 (id)
BR (1) BR0008280A (id)
CA (1) CA2362831C (id)
CZ (1) CZ20012980A3 (id)
DE (1) DE60014588T2 (id)
DK (1) DK1154993T3 (id)
ES (1) ES2228458T3 (id)
HK (1) HK1044330A1 (id)
HR (1) HRP20010595B1 (id)
HU (1) HUP0200155A3 (id)
ID (1) ID30129A (id)
IL (2) IL144636A0 (id)
MA (1) MA26769A1 (id)
NO (1) NO20014018D0 (id)
NZ (1) NZ513254A (id)
PL (1) PL349461A1 (id)
PT (1) PT1154993E (id)
RU (1) RU2245874C2 (id)
SI (1) SI1154993T1 (id)
TR (1) TR200102399T2 (id)
WO (1) WO2000048994A1 (id)
YU (1) YU58701A (id)
ZA (1) ZA200106180B (id)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6939855B2 (en) 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method
US6680195B1 (en) * 1997-11-26 2004-01-20 Inhibitex, Inc. Extracellular matrix-binding proteins from staphylococcus aureus
US6521626B1 (en) * 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
US6380387B1 (en) 1999-12-06 2002-04-30 Hoffmann-La Roche Inc. 4-Pyrimidinyl-n-acyl-l phenylalanines
US6388084B1 (en) 1999-12-06 2002-05-14 Hoffmann-La Roche Inc. 4-pyridinyl-n-acyl-l-phenylalanines
EP2267045B1 (en) * 2000-01-26 2015-07-15 Mitsui Chemicals, Inc. Olefin polymer of very low polydispersity and process for preparing the same
EP1270547A4 (en) 2000-03-23 2005-07-13 Ajinomoto Kk NEW PHENYL ALANIDE DERIVATIVES
US6960597B2 (en) * 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
ES2252310T3 (es) * 2000-09-14 2006-05-16 Grunenthal Gmbh Beta-tioaminoacidos.
US20050026879A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20090297611A1 (en) * 2003-07-31 2009-12-03 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050069227A1 (en) * 2003-09-29 2005-03-31 Mark Steele Flexible package having integrated slit member
US20050176755A1 (en) * 2003-10-31 2005-08-11 Dyatkin Alexey B. Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists
AR047537A1 (es) * 2004-02-10 2006-01-25 Janssen Pharmaceutica Nv Piridazinonaureas como antagonistas de integrinas
KR20070004676A (ko) * 2004-02-10 2007-01-09 얀센 파마슈티카 엔.브이. 알파4 인테그린의 길항제로서의 피리다지논
AU2005222074B2 (en) * 2004-03-10 2011-02-17 Merck Sharp & Dohme Corp. VLA-4 antagonists
US7776891B2 (en) * 2004-08-16 2010-08-17 Merck Sharp & Dohme Corp. VLA-4 antagonists
US7641325B2 (en) * 2004-10-04 2010-01-05 Kodak Graphic Communications Group Canada Non-conductive fluid droplet characterizing apparatus and method
WO2006081986A1 (en) * 2005-02-07 2006-08-10 F.Hoffmann-La Roche Ag Bambuterol and integrin inhibitor combination
WO2006094640A2 (en) * 2005-03-04 2006-09-14 F.Hoffmann-La Roche Ag Roflumilast and integrin inhibitor combination and method of treatment
CZ297581B6 (cs) * 2005-05-26 2007-01-10 Universita Karlova v Praze, Farmaceutická fakulta v Hradci Králové Antimykotické a antimykobakteriální thiosalicylanilidy a způsob jejich přípravy
AU2006337137B2 (en) * 2005-12-29 2012-06-14 Tersera Therapeutics Llc Multicyclic amino acid derivatives and methods of their use
CA2714335A1 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
KR101811965B1 (ko) * 2007-11-07 2017-12-22 셀덱스 쎄라퓨틱스, 인크. 인간 수지상 및 상피 세포 205(dec-205)에 결합하는 항체
KR20110008086A (ko) 2008-04-11 2011-01-25 메리맥 파마슈티컬즈, 인크. 인간 혈청 알부민 링커 및 그 콘쥬게이트
US8927694B2 (en) 2008-11-18 2015-01-06 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
US8343706B2 (en) 2010-01-25 2013-01-01 International Business Machines Corporation Fluorine-free fused ring heteroaromatic photoacid generators and resist compositions containing the same
EP2769223A1 (en) 2011-10-17 2014-08-27 Westfälische Wilhelms-Universität Münster Assessment of pml risk and methods based thereon
US9345766B2 (en) 2012-08-30 2016-05-24 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-ERBB3 agents
EP3873897B1 (en) 2018-10-30 2024-08-14 Gilead Sciences, Inc. N-benzoyl-phenylalanine derivatives as alpha4beta7 integrin inhibitors for treating inflammatory diseases
EP3873900A1 (en) 2018-10-30 2021-09-08 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
WO2020092375A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
CN114222730B (zh) 2019-08-14 2024-09-10 吉利德科学公司 用于抑制α4β7整合素的化合物
CN113683499B (zh) * 2021-09-10 2024-01-30 上海皓鸿生物医药科技有限公司 一种制备杜韦利西布中间体的方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE584914A (id) 1958-11-24
US3527793A (en) 1967-08-18 1970-09-08 Bristol Myers Co Phenylglycine derivatives
IT1190378B (it) 1985-06-21 1988-02-16 Isf Spa Derivati pirrolidonici
US5039805A (en) 1988-12-08 1991-08-13 Hoffmann-La Roche Inc. Novel benzoic and phenylacetic acid derivatives
US5463116A (en) 1991-07-30 1995-10-31 Ajinomoto Co., Inc. Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
DE69524598T2 (de) 1994-06-20 2002-07-11 Takeda Chemical Industries, Ltd. Kondensierte imidazolderivate, ihre herstellung und verwendung
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
US5804595A (en) 1995-12-05 1998-09-08 Regents Of The University Of Minnesota Kappa opioid receptor agonists
DE19548709A1 (de) 1995-12-23 1997-07-03 Merck Patent Gmbh Tyrosinderivate
WO1997036859A1 (en) * 1996-03-29 1997-10-09 G.D. Searle & Co. Para-substituted phenylpropanoic acid derivatives as integrin antagonists
DE69706407T2 (de) 1996-03-29 2002-05-29 G.D. Searle & Co., Chicago META-SUBSTITUIERTE PHENYLENDERIVATE UND IHRE VERWENDUNG ALS ALPHAvBETA3 INTERGRIN-ANTAGONISTEN ODER INHIBITOREN
DE19654483A1 (de) 1996-06-28 1998-01-02 Merck Patent Gmbh Phenylalanin-Derivate
JP2002512625A (ja) * 1997-05-29 2002-04-23 メルク エンド カンパニー インコーポレーテッド 細胞接着阻害薬としての複素環アミド化合物
ATE249421T1 (de) * 1997-06-23 2003-09-15 Tanabe Seiyaku Co Inhibitoren der alpha4-beta1 vermittelten zelladhäsion
CN1265674A (zh) * 1997-07-31 2000-09-06 伊兰药品公司 能抑制由vla-4介导的白细胞粘连的4-氨基苯基丙氨酸化合物
JP2001512139A (ja) * 1997-07-31 2001-08-21 エラン・ファーマシューティカルズ・インコーポレーテッド Vla−4が介在する白血球接着を阻害するスルホニル化ジペプチド化合物
EP0994895A1 (en) * 1997-07-31 2000-04-26 Elan Pharmaceuticals, Inc. Dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4
US6229011B1 (en) * 1997-08-22 2001-05-08 Hoffman-La Roche Inc. N-aroylphenylalanine derivative VCAM-1 inhibitors
JP3555876B2 (ja) * 1997-08-22 2004-08-18 エフ.ホフマン−ラ ロシュ アーゲー N−アロイルフェニルアラニン誘導体
CN1276785A (zh) 1997-08-22 2000-12-13 霍夫曼-拉罗奇有限公司 N-烷酰基苯丙氨酸衍生物
HUP0101701A3 (en) * 1997-12-23 2003-02-28 Aventis Pharma Ltd West Mallin Substituted betha-alanines and pharmaceutical compositions comprising them
AU3260399A (en) 1998-02-26 1999-09-15 Celltech Therapeutics Limited Phenylalanine derivatives as inhibitors of alpha4 integrins
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds

Also Published As

Publication number Publication date
YU58701A (sh) 2004-05-12
EP1154993A1 (en) 2001-11-21
KR20010102243A (ko) 2001-11-15
US20020010338A1 (en) 2002-01-24
HUP0200155A2 (en) 2002-06-29
ID30129A (id) 2001-11-08
RU2245874C2 (ru) 2005-02-10
US6426348B1 (en) 2002-07-30
IL144636A0 (en) 2002-05-23
US6458844B2 (en) 2002-10-01
AU2547500A (en) 2000-09-04
AU773388B2 (en) 2004-05-27
US20020052508A1 (en) 2002-05-02
DE60014588T2 (de) 2006-02-23
US20020028933A1 (en) 2002-03-07
CN1213025C (zh) 2005-08-03
JP2002537286A (ja) 2002-11-05
NO20014018L (no) 2001-08-17
NZ513254A (en) 2003-10-31
HK1044330A1 (en) 2002-10-18
WO2000048994A1 (en) 2000-08-24
CA2362831C (en) 2008-10-07
US6479666B2 (en) 2002-11-12
CA2362831A1 (en) 2000-08-24
PL349461A1 (en) 2002-07-29
IL144636A (en) 2007-06-17
TR200102399T2 (tr) 2002-01-21
PT1154993E (pt) 2005-01-31
ES2228458T3 (es) 2005-04-16
DE60014588D1 (en) 2004-11-11
US6288267B1 (en) 2001-09-11
KR100649819B1 (ko) 2007-02-28
EP1154993B1 (en) 2004-10-06
CZ20012980A3 (cs) 2002-04-17
DK1154993T3 (da) 2005-02-14
ATE278664T1 (de) 2004-10-15
BR0008280A (pt) 2001-11-06
HRP20010595B1 (en) 2006-02-28
US6423728B1 (en) 2002-07-23
NO20014018D0 (no) 2001-08-17
CN1342140A (zh) 2002-03-27
ZA200106180B (en) 2002-10-28
US20020040148A1 (en) 2002-04-04
HRP20010595A2 (en) 2002-08-31
US20010041799A1 (en) 2001-11-15
HUP0200155A3 (en) 2005-04-28
MA26769A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
PL349461A1 (en) Thioamide derivatives
BG108806A (en) IIb/IIIa CELL ADHESION INHIIBITORS, METHOD FOR THE PRODUCTION, PHARMACEUTCIAL COMPOSITION AND ADMINISTRATION THEREOF
MXPA01008058A (es) Composiciones deinhibidor de cicloxigenasa-2 teniendo un rapido inicio de efecto terapeutico.
MY126972A (en) 4-pyrimidinyl-n-acyl-l-phenylalanines
WO2005051906A3 (en) Heterocyclic inhibitors of mek and methods of use thereof
TW200716648A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
CA2505964A1 (en) Pharmaceutical compositions and dosage forms of thalidomide
IL179013A0 (en) Combinations of glycopyrrolate and
YU40502A (sh) 4-piridinil-n-acil-l-fenilalanini
EP1539136A4 (en) PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS
AU2003224923A1 (en) Heterocyclic amide derivatives as cytokine inhibitors
DE60016181D1 (de) C-16 ungesätigte fp-selektive prostaglandin analoge
CA2362833A1 (en) Phenylalaninol derivatives
PL1716147T3 (pl) Pochodne diazaspiropiperydyny jako inhibitory transportera 1 glicyny i transportera 2 glicyny
EP1619184A3 (en) Urea compounds as kinase inhibitors
WO1998057910A3 (en) Cyclooxygenase-i selective inhibitors and the use thereof as analgesic, antiinflammatory and antiarthritic agents